Avipendekin pegol - Nektar Therapeutics
Alternative Names: NKTR-255; Polymer-conjugated IL-15 - Nektar TherapeuticsLatest Information Update: 14 Aug 2024
At a glance
- Originator Nektar Therapeutics
- Developer AbelZeta Pharma; Fred Hutchinson Cancer Research Center; Gilead Sciences; Janssen; M. D. Anderson Cancer Center; Merck KGaA; Nektar Therapeutics; Stanford University
- Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III B-cell lymphoma; Diffuse large B cell lymphoma
- Phase II Non-small cell lung cancer; Urogenital cancer
- Phase I/II Cervical cancer; Colorectal cancer; Squamous cell cancer
- Phase I Multiple myeloma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Preclinical Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Triple negative breast cancer
- Research Viral infections
Most Recent Events
- 08 Aug 2024 Efficacy data from a phase I trial in B-cell lymphoblastic leukaemia lymphoma released by Nektar Therapeutics
- 11 Dec 2023 Pharmacodynamics data from a preclinical trial in Burkitt's lymphoma released by Nektar Therapeutics
- 09 Dec 2023 Updated pharmacodynamics data from a preclinical studies in Burkitt Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)